N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=1,638 Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Breast Cancer
Primary: Cancer Detection Rate Per 1000 Women Screened, by Breast Density — 3.2; 12.0; 10.7; 0 cancers per 1000 women screened — p=<0.001
N/A N=1,007 Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
N/A N=969 Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Breast Cancer
Primary: Diagnostic Yield — 3.2; 9.6; 10.7 cancers per 1000 women screened — p=.016
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
N/A N=451 Project Breast47: Effect of an Educational Intervention
Breast Neoplasm · Primary Prevention · Risk Factors
Primary: Behavioral BC Risk With an Educational Intervention for Prevention — 8.10; 8.15 units on a scale
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
N/A N=1 Prostate Cancer Screening in Men With Germline BRCA2 Mutations
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Phase 2 N=100 Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer
Breast Neoplasms
Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 2 N=37 Stellate Ganglion Block (SGB) For Women for Breast Cancer
Hot Flushes · Hot Flashes
Primary: Change in Number of Night Sweats From Baseline to 6 Months After Intervention. — 5.46; 10.09 night sweats/month
N/A N=36,444 Surveillance Imaging Modalities for Breast Cancer Assessment
Breast Cancer
Primary: Number of Breast Cancers Detected — 279; 27 cancers detected
Phase 2 N=30 Denosumab and MRI Breast Imaging
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
N/A N=670 Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
Breast Cancer Related Lymphedema · Covid19
Primary: COVID-19 Vaccination on Contralateral vs Ipsilateral Arm — 432; 435; 331; 122 Participants
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
N/A N=324 Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer
Ductal Breast Cancer
Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…
N/A N=50,343 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs
Breast Cancer
Primary: Breast Cancer Risk — 1076; 1068 participants
Phase 2 N=1,075 Green Tea and Reduction of Breast Cancer Risk
Breast Cancer
Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent
Phase 2 N=48 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) — 6.6; 3.8 Months — p=0.12
Phase 2 N=25 Partial Breast Irradiation With Chemotherapy
Breast Cancer
Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants
N/A N=206 Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Breast Cancer
Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR
Phase 2 N=72 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71
Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
N/A N=132 Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening
Breast Cancer
Primary: Area Under the Curve for Cancer Detection Rates of CESM Compared With Breast MRI for Breast Cancer Screening — 0.91; .91 Probability of malignancy
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
N/A N=29 Magnetic Seed Localisation of Breast Cancers
Breast Cancer
Primary: Migration of Sentimark Device — 100 percentage of Magseed migrating >10mm